This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Naturally, this news comes much to the chagrin of Big Pharma as well. Those on the left have long pretended to crusade against Big Pharma, promising to finally rein in drug companies like Pfizer ...

The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations. Ben Hargreaves explores what is driving this ...

Big Pharma executives feel optimistic about their industry’s trajectory under a second Donald Trump presidency, with regulation rollbacks and other changes likely to boost bottom lines for drugmakers, ...

Even more recently, AbbVie has joined the list of big pharma admirers of ADCs to launch ... its commercial interest in the area has come full circle: from pulling the first ADC from the market ...